Rein Therapeutics Inc.
RNTXNASDAQHealthcare● Active
$0.95
+$0.01(+0.59%)
Market Cap$26521833
P/E Ratio—
52W High$2.18
52W Low$0.915
Rein Therapeutics Inc. (RNTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RNTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.19
Est. -$0.49 · +61.2%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
RNTX reports quarterly as a NASDAQ-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.27 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.49 | -$0.19 | +61.2% | — | — | — |
| — Q1 FY2026 | Mar 26, 2026 | -$1.09 | -$1.09 | +0.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.24 | -$0.21 | +12.5% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.22 | -$0.28 | -27.3% | — | — | — |
| ▼ Q2 FY2025 | Apr 7, 2025 | -$0.14 | -$0.26 | -85.7% | — | — | — |
| ▼ Q4 FY2024 | Dec 31, 2024 | -$0.46 | -$1.89 | -310.7% | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.25 | -$0.27 | -8.0% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.27
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.49
EPS Surpr.
+61.2%
Revenue
—
Q1 FY2026
Mar 26, 2026
EPS Actual
-$1.09
EPS Est.
-$1.09
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.24
EPS Surpr.
+12.5%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.22
EPS Surpr.
-27.3%
Revenue
—
Q2 FY2025
Apr 7, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.14
EPS Surpr.
-85.7%
Revenue
—
Q4 FY2024
Dec 31, 2024Miss
EPS Actual
-$1.89
EPS Est.
-$0.46
EPS Surpr.
-310.7%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.27
EPS Est.
-$0.25
EPS Surpr.
-8.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q3 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q2 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q1 FY2026 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q4 FY2025 | $-1.09 | $-1.09 | $-1.09 | 1 |
| Q3 FY2025 | $-0.26 | $-0.24 | $-0.22 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +61.2% | $1.13 | $1.05 | -7.08% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +0.0% | $1.30 | $1.27 | -2.31% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +12.5% | $1.35 | $1.25 | -7.41% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -27.3% | $1.20 | $1.16 | -3.33% |
| ▼ Q2 FY2025 | Apr 7, 2025 | -85.7% | $1.70 | $1.64 | -3.53% |
| ▼ Q4 FY2024 | Dec 31, 2024 | -310.7% | $2.32 | $2.30 | -0.86% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -8.0% | No price data | $2.12 | — |
| ▼ Q3 FY2024 | Aug 14, 2024 | -80.0% | No price data | $2.12 | — |
Q2 FY2026-7.08%
Report Date
May 15, 2026
EPS Beat/Miss
+61.2%
Price Before
$1.13
Price After
$1.05
Q1 FY2026-2.31%
Report Date
Mar 26, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.30
Price After
$1.27
Q4 FY2025-7.41%
Report Date
Nov 14, 2025
EPS Beat/Miss
+12.5%
Price Before
$1.35
Price After
$1.25
Q3 FY2025-3.33%
Report Date
Aug 14, 2025
EPS Beat/Miss
-27.3%
Price Before
$1.20
Price After
$1.16
Q2 FY2025-3.53%
Report Date
Apr 7, 2025
EPS Beat/Miss
-85.7%
Price Before
$1.70
Price After
$1.64
Q4 FY2024-0.86%
Report Date
Dec 31, 2024
EPS Beat/Miss
-310.7%
Price Before
$2.32
Price After
$2.30
Q4 FY2024—
Report Date
Nov 14, 2024
EPS Beat/Miss
-8.0%
Price Before
—
Price After
$2.12
Q3 FY2024—
Report Date
Aug 14, 2024
EPS Beat/Miss
-80.0%
Price Before
—
Price After
$2.12
Avg Beat Reaction-5.60%
Avg Miss Reaction-2.57%
Beat Rate3 / 8 quarters
Largest Move-7.41% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RNTX ends December
Rein Therapeutics Inc. (RNTX) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.19 — beating the analyst consensus of $-0.49 by +61.2%. RNTX has beaten EPS estimates for 3 consecutive quarters. The next RNTX earnings date is expected around September 1, 2026.
Each quarter, investors track RNTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RNTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RNTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RNTX earnings · 5 questionsRein Therapeutics Inc.'s next earnings report is expected around September 1, 2026. RNTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RNTX historically reports after market close (AMC).
RNTX earnings datewhen is RNTX earningsRNTX next earnings datewhen does RNTX report earningsRNTX earnings calendar
▸ Source: FMP · Rein Therapeutics Inc. SEC filings · US GAAP · Rein Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026